Aspire Private Capital LLC bought a new position in AstraZeneca plc (NYSE:AZN) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 7,587 shares of the company’s stock, valued at approximately $288,000.
A number of other institutional investors and hedge funds have also recently modified their holdings of AZN. Berman Capital Advisors LLC bought a new position in shares of AstraZeneca in the fourth quarter valued at approximately $38,000. Portfolio Solutions LLC purchased a new stake in shares of AstraZeneca during the fourth quarter valued at approximately $40,000. Sontag Advisory LLC purchased a new stake in shares of AstraZeneca during the fourth quarter valued at approximately $40,000. CNB Bank increased its position in shares of AstraZeneca by 245.0% during the fourth quarter. CNB Bank now owns 1,080 shares of the company’s stock valued at $41,000 after acquiring an additional 767 shares during the last quarter. Finally, Loeb Partners Corp purchased a new stake in shares of AstraZeneca during the fourth quarter valued at approximately $46,000. 18.31% of the stock is owned by institutional investors and hedge funds.
NYSE:AZN traded up $0.03 during trading hours on Friday, hitting $38.80. 5,430,254 shares of the company’s stock traded hands, compared to its average volume of 6,593,181. The firm has a market capitalization of $98.28 billion, a price-to-earnings ratio of 11.21, a P/E/G ratio of 1.19 and a beta of 0.51. AstraZeneca plc has a 52 week low of $34.38 and a 52 week high of $43.29. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.78 and a current ratio of 0.96.
The business also recently announced a semiannual dividend, which was paid on Wednesday, March 27th. Stockholders of record on Friday, March 1st were paid a $0.95 dividend. This represents a dividend yield of 4.64%. The ex-dividend date was Thursday, February 28th. This is a positive change from AstraZeneca’s previous semiannual dividend of $0.45. AstraZeneca’s payout ratio is 53.76%.
A number of brokerages recently commented on AZN. Zacks Investment Research raised AstraZeneca from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research report on Thursday, April 4th. ValuEngine downgraded AstraZeneca from a “buy” rating to a “hold” rating in a research report on Monday, April 1st. Cowen raised AstraZeneca from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $42.00 to $48.00 in a research report on Monday, April 1st. UBS Group downgraded AstraZeneca from a “neutral” rating to a “sell” rating and set a $40.73 target price for the company. in a research report on Tuesday, April 2nd. Finally, BNP Paribas began coverage on AstraZeneca in a research report on Tuesday, February 5th. They issued an “outperform” rating for the company. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $45.29.
ILLEGAL ACTIVITY NOTICE: “7,587 Shares in AstraZeneca plc (AZN) Acquired by Aspire Private Capital LLC” was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.baseballdailydigest.com/news/2019/04/21/aspire-private-capital-llc-buys-shares-of-7587-astrazeneca-plc-azn.html.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: Analyzing a company’s cash flow statement
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.